Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice.

Villa-Pérez P, Merino B, Fernández-Díaz CM, Cidad P, Lobatón CD, Moreno A, Muturi HT, Ghadieh HE, Najjar SM, Leissring MA, Cózar-Castellano I, Perdomo G.

Metabolism. 2018 Nov;88:1-11. doi: 10.1016/j.metabol.2018.08.001. Epub 2018 Aug 8.

2.

Development and Characterization of Quantitative, High-Throughput-Compatible Assays for Proteolytic Degradation of Glucagon.

Suire CN, Lane S, Leissring MA.

SLAS Discov. 2018 Dec;23(10):1060-1069. doi: 10.1177/2472555218786509. Epub 2018 Jul 11.

PMID:
29995452
3.

Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display.

Suire CN, Nainar S, Fazio M, Kreutzer AG, Paymozd-Yazdi T, Topper CL, Thompson CR, Leissring MA.

PLoS One. 2018 Feb 15;13(2):e0193101. doi: 10.1371/journal.pone.0193101. eCollection 2018.

4.

Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro.

Hogan MF, Meier DT, Zraika S, Templin AT, Mellati M, Hull RL, Leissring MA, Kahn SE.

Endocrinology. 2016 Sep;157(9):3462-8. doi: 10.1210/en.2016-1410. Epub 2016 Jul 12.

5.

Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease.

Leissring MA.

CNS Drugs. 2016 Aug;30(8):667-75. doi: 10.1007/s40263-016-0364-1. Review.

PMID:
27349988
6.

Age and its association with low insulin and high amyloid-β peptides in blood.

Li H, Zhu H, Wallack M, Mwamburi M, Abdul-Hay SO, Leissring MA, Qiu WQ.

J Alzheimers Dis. 2016;49(1):129-37. doi: 10.3233/JAD-150428.

7.

Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors.

Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, Hodder P, Leissring MA.

ACS Chem Biol. 2015 Dec 18;10(12):2716-24. doi: 10.1021/acschembio.5b00334. Epub 2015 Sep 30.

PMID:
26398879
8.

Aβ degradation-the inside story.

Leissring MA.

Front Aging Neurosci. 2014 Aug 26;6:229. doi: 10.3389/fnagi.2014.00229. eCollection 2014. No abstract available.

9.

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.

Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR.

Nature. 2014 Jul 3;511(7507):94-8. doi: 10.1038/nature13297. Epub 2014 May 21.

10.

ML345, A Small-Molecule Inhibitor of the Insulin-Degrading Enzyme (IDE).

Bannister TD, Wang H, Abdul-Hay SO, Masson A, Madoux F, Ferguson J, Mercer BA, Schurer S, Zuhl A, Cravatt BF, Leissring MA, Hodder P.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2014 May 13].

11.

The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme.

Kurklinsky S, Abdul-Hay SO, McGuire MP, Howard EA, Knight J, Leissring MA.

Horm Metab Res. 2014 Jan;46(1):73-4. doi: 10.1055/s-0033-1353211. Epub 2013 Aug 23. No abstract available.

PMID:
23975847
12.

Regulation of distinct pools of amyloid β-protein by multiple cellular proteases.

Leissring MA, Turner AJ.

Alzheimers Res Ther. 2013 Aug 13;5(4):37. doi: 10.1186/alzrt194. eCollection 2013. Review.

13.

Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.

Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA.

J Med Chem. 2013 Mar 28;56(6):2246-55. doi: 10.1021/jm301280p. Epub 2013 Mar 15.

PMID:
23437776
14.

Identification of BACE2 as an avid ß-amyloid-degrading protease.

Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA.

Mol Neurodegener. 2012 Sep 17;7:46. doi: 10.1186/1750-1326-7-46.

15.

Proteolytic degradation of amyloid β-protein.

Saido T, Leissring MA.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a006379. doi: 10.1101/cshperspect.a006379. Review.

16.

Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?

Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ.

J Alzheimers Dis. 2012;29(2):329-40. doi: 10.3233/JAD-2011-111472.

17.

Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance.

Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA.

PLoS One. 2011;6(6):e20818. doi: 10.1371/journal.pone.0020818. Epub 2011 Jun 9.

18.

Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging.

Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, McGowan E, Dickson DW, Lewis J.

Am J Pathol. 2010 Jul;177(1):311-24. doi: 10.2353/ajpath.2010.090915. Epub 2010 Jun 3. Erratum in: Am J Pathol. 2010 Oct;177(4):2146. Wuertzer, Charles A [added].

19.

Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.

Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang WJ, Stein RL, Cuny GD, Selkoe DJ.

PLoS One. 2010 May 7;5(5):e10504. doi: 10.1371/journal.pone.0010504.

20.

Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.

Delledonne A, Kouri N, Reinstatler L, Sahara T, Li L, Zhao J, Dickson DW, Ertekin-Taner N, Leissring MA.

Mol Neurodegener. 2009 Oct 16;4:39. doi: 10.1186/1750-1326-4-39.

21.

Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life.

Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM.

Neurobiol Dis. 2009 Nov;36(2):293-302. doi: 10.1016/j.nbd.2009.07.021. Epub 2009 Aug 4.

22.

Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening.

Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, Yeh LA, Cuny GD, Stein RL, Selkoe DJ, Leissring MA.

PLoS One. 2009;4(4):e5274. doi: 10.1371/journal.pone.0005274. Epub 2009 Apr 22.

23.

Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.

Zhao J, Li L, Leissring MA.

Mol Neurodegener. 2009 Jan 14;4:4. doi: 10.1186/1750-1326-4-4.

24.

The AbetaCs of Abeta-cleaving proteases.

Leissring MA.

J Biol Chem. 2008 Oct 31;283(44):29645-9. doi: 10.1074/jbc.R800022200. Epub 2008 Aug 22. Review.

25.

Molecular basis for the thiol sensitivity of insulin-degrading enzyme.

Neant-Fery M, Garcia-Ordoñez RD, Logan TP, Selkoe DJ, Li L, Reinstatler L, Leissring MA.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9582-7. doi: 10.1073/pnas.0801261105. Epub 2008 Jul 8.

26.

Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin.

Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM.

Neurobiol Dis. 2008 Sep;31(3):442-50. doi: 10.1016/j.nbd.2008.06.001. Epub 2008 Jun 17.

27.

The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.

Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, Roher AE, de Prat Gay G, Morelli L, Castaño EM.

J Biol Chem. 2008 Jun 20;283(25):17039-48. doi: 10.1074/jbc.M706316200. Epub 2008 Apr 14.

28.

Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.

Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ.

J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5.

29.

Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ.

Am J Pathol. 2007 Jul;171(1):241-51.

30.

Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.

Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE.

J Biol Chem. 2007 Mar 16;282(11):7825-32. Epub 2007 Jan 22.

31.

Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease.

Leissring MA.

Curr Alzheimer Res. 2006 Dec;3(5):431-5. Review.

PMID:
17168642
32.

Structural biology: enzyme target to latch on to.

Leissring MA, Selkoe DJ.

Nature. 2006 Oct 19;443(7113):761-2. No abstract available.

PMID:
17051198
33.

Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.

Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ.

Biochemistry. 2005 May 3;44(17):6513-25.

PMID:
15850385
34.

Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria.

Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ.

Biochem J. 2004 Nov 1;383(Pt. 3):439-46.

35.

Live discussion: how the other half lives - or the what, how, and where, of the AbetaPP intracellular domain.

Bishop G, Coleman P, Crutcher K, David D, Kinoshita J, LaFerla F, Leissring M, Shepherd J, Therianos S, Wang R, Wilson A, Zhu M.

J Alzheimers Dis. 2004 Apr;6(2):193-9. No abstract available.

PMID:
15171221
36.

Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.

Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ.

Am J Pathol. 2004 Apr;164(4):1425-34.

37.

Live discussion: Amyloid-beta degradation: the forgotten half of Alzheimer's disease. 12 September 2002.

Whitaker C, Eckman C, Almeida C, Feinstein D, Atwood C, Eckman E, Crutcher K, Hersh L, Leissring M, LaVoie M, Ertekin-Taner N, Shapiro P, Takahashi R, Yamin R, Mansourian S, Estus S, Lesné S, Turner T, Farris W, Stroebel G.

J Alzheimers Dis. 2003 Dec;5(6):491-7. No abstract available.

PMID:
14765518
38.

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ.

Neuron. 2003 Dec 18;40(6):1087-93.

39.

Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays.

Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, Selkoe DJ.

J Biol Chem. 2003 Sep 26;278(39):37314-20. Epub 2003 Jul 16.

40.

Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle.

Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6334-9. Epub 2002 Apr 23.

41.

A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP.

Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Müller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4697-702. Epub 2002 Mar 26.

42.

Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling.

Leissring MA, LaFerla FM, Callamaras N, Parker I.

Neurobiol Dis. 2001 Jun;8(3):469-78.

PMID:
11442355
43.

Multiphoton-evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling.

Marchant JS, Stutzmann GE, Leissring MA, LaFerla FM, Parker I.

Nat Biotechnol. 2001 Jul;19(7):645-9.

PMID:
11433276
44.

Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma.

LaFerla FM, Sugarman MC, Lane TE, Leissring MA.

J Mol Neurosci. 2000 Aug;15(1):45-59.

PMID:
11211236
45.

Calsenilin reverses presenilin-mediated enhancement of calcium signaling.

Leissring MA, Yamasaki TR, Wasco W, Buxbaum JD, Parker I, LaFerla FM.

Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8590-3.

46.

Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice.

Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM.

J Cell Biol. 2000 May 15;149(4):793-8.

47.

Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders.

Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD.

Trends Neurosci. 2000 May;23(5):222-9. Review.

PMID:
10782128
48.
49.

Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes.

Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM.

J Neurochem. 1999 Mar;72(3):1061-8.

50.

Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy.

Leissring MA, Sugarman MC, LaFerla FM.

Drugs Aging. 1998 Sep;13(3):193-8. Review.

PMID:
9789723

Supplemental Content

Loading ...
Support Center